EDIT
Price
$2.49
Change
-$0.02 (-0.80%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
385.49M
18 days until earnings call
Intraday BUY SELL Signals
RNAC
Price
$6.41
Change
-$0.01 (-0.16%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
194.24M
14 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

EDIT vs RNAC

EDIT vs RNAC Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
EDIT vs. RNAC commentary
Oct 22, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDIT is a Hold and RNAC is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for EDIT with price predictions
Oct 21, 2026

Momentum Indicator for EDIT turns negative, indicating new downward trend

EDIT saw its Momentum Indicator move below the 0 level on October 13, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 84 similar instances where the indicator turned negative. In 77 of the 84 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for EDIT turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 43 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.

EDIT moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for EDIT entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 47 of 63 cases where EDIT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.

Following a +9.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in 179 of 224 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

EDIT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.661) is normal, around the industry mean (2.988). P/E Ratio (-3.803) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (5.855) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 72 (best 1 - 100 worst), indicating slightly worse than average price growth. EDIT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for RNAC with price predictions
Oct 21, 2026

RNAC in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 14, 2026

RNAC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 38 of 44 cases where RNAC's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where RNAC's RSI Oscillator exited the oversold zone, 37 of 44 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.

The Moving Average Convergence Divergence (MACD) for RNAC just turned positive on October 21, 2026. Looking at past instances where RNAC's MACD turned positive, the stock continued to rise in 37 of 45 cases over the following month. The odds of a continued upward trend are 82%.

Following a +5.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where RNAC advanced for three days, in 218 of 262 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RNAC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for RNAC entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.551) is normal, around the industry mean (2.988). P/E Ratio (-1.111) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (144.928) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. RNAC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RNAC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
EDIT vs RNAC: Fundamental Ratings
EDIT
RNAC
OUTLOOK RATING
1..100
8168
VALUATION
overvalued / fair valued / undervalued
1..100
54
Fair valued
28
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
7278
P/E GROWTH RATING
1..100
2620
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RNAC's Valuation (28) in the Biotechnology industry is in the same range as EDIT (54). This means that RNAC’s stock grew similarly to EDIT’s over the last 12 months.

RNAC's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as EDIT (100). This means that RNAC’s stock grew similarly to EDIT’s over the last 12 months.

EDIT's SMR Rating (99) in the Biotechnology industry is in the same range as RNAC (100). This means that EDIT’s stock grew similarly to RNAC’s over the last 12 months.

EDIT's Price Growth Rating (72) in the Biotechnology industry is in the same range as RNAC (78). This means that EDIT’s stock grew similarly to RNAC’s over the last 12 months.

RNAC's P/E Growth Rating (20) in the Biotechnology industry is in the same range as EDIT (26). This means that RNAC’s stock grew similarly to EDIT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EDITRNAC
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
75%
N/A
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
MACD
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 2 days ago
83%
Declines
ODDS (%)
Bearish Trend 9 days ago
90%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Oct 22, 2026
Stock price -- (EDIT: $2.51 vs. RNAC: $6.42)
Brand notoriety: EDIT and RNAC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EDIT: 34% vs. RNAC: 71%
Market capitalization -- EDIT: $385.49M vs. RNAC: $194.24M
EDIT [@Biotechnology] is valued at $385.49M. RNAC’s [@Biotechnology] market capitalization is $194.24M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $132.95B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EDIT’s FA Score shows that 1 FA rating(s) are green while RNAC’s FA Score has 2 green FA rating(s).

  • EDIT’s FA Score: 1 green, 4 red.
  • RNAC’s FA Score: 2 green, 3 red.
According to our system of comparison, RNAC is a better buy in the long-term than EDIT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EDIT’s TA Score shows that 3 TA indicator(s) are bullish while RNAC’s TA Score has 4 bullish TA indicator(s).

  • EDIT’s TA Score: 3 bullish, 5 bearish.
  • RNAC’s TA Score: 4 bullish, 2 bearish.
According to our system of comparison, RNAC is a better buy in the short-term than EDIT.

Price Growth

EDIT (@Biotechnology) experienced а +10.57% price change this week, while RNAC (@Biotechnology) price change was +1.26% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.

Reported Earning Dates

EDIT is expected to report earnings on Nov 09, 2026.

RNAC is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (-1.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
EDIT
Daily Signal:
Gain/Loss:
RNAC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

RNAC and

Correlation & Price change

A.I.dvisor indicates that over the last year, RNAC has been closely correlated with TAOX. These tickers have moved in lockstep 91% of the time. This A.I.-generated data suggests there is a high statistical probability that if RNAC jumps, then TAOX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RNAC
1D Price
Change %
RNAC100%
+0.39%
TAOX - RNAC
91%
Closely correlated
+4.88%
PALI - RNAC
81%
Closely correlated
-2.10%
EDIT - RNAC
46%
Loosely correlated
-2.71%
NKTX - RNAC
45%
Loosely correlated
+0.57%
SLDB - RNAC
41%
Loosely correlated
+0.16%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
VET.X0.0076220.000446
+6.21%
VeChain cryptocurrency
LQTY.X0.2161370.012079
+5.92%
Liquity cryptocurrency
VTHO.X0.0006800.000035
+5.46%
VeThor Token cryptocurrency
ANY.X0.0295030.000868
+3.03%
Anyspend cryptocurrency
SCRT.X0.0071240.000080
+1.14%
Secret cryptocurrency